SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves quarterly results beat expectations and raised guidance, with a large revenue backlog and customer prepayments bolstering the AI-compute demand story and easing some financing concerns. The community reaction is split: bulls see stronger execution and potential short covering, while bears remain focused on heavy debt, interest costs and cash burn; the stocks muted, volatile response drew particular attention.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlists Q3 results and outlook are driving attention, with traders focused on improved profitability and recurring Samsung and Micron licensing revenue expected to bolster future quarters. The reaction is mostly bullish, though some question the decline in product sales and are disappointed that the call provided no concrete SK Hynix or Nasdaq-uplisting update; speculation about a Hynix deal remains unconfirmed.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the Nov. 22 FDA decision on Capricors deramiocel application for Duchenne muscular dystrophy; management said the application is in final review and described launch preparations. Many traders read CEO Linda Marbns confident Q3-call remarks as encouraging, while others caution that the outcome remains uncertain given FDA concerns and the applications binary risk.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Scrutiny of CEO Jensen Huang over his relationship with a woman alleged to have ties to Chinese intelligenceand questions about Nvidia chip shipments to Chinais driving concern about governance, export controls, and whether Huang could remain CEO; the allegations have not established that company secrets were compromised. Traders are split between viewing the selloff as an oversold buying opportunity ahead of earnings and fearing further fallout from the investigations and shareholder litigation.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigettis Q3 results missed expectations, particularly on revenue, prompting a sharp selloff and renewed criticism of its high valuation, cash burn, and slow path to commercialization. Some traders remain optimistic about its quantum technology and long-term prospects, but that view is competing with concerns that technical progress and government support have yet to translate into meaningful business growth.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costcos announcement of a large special cash dividend and renewed share-buyback authorization is driving the discussion. Many traders welcome the shareholder payout and are bullish on the stock, while others argue the dividend is not free money and that Costcos valuation remains expensive.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius quarterly results are driving attention: revenue growth, expanding gross margins and raised full-year guidance were offset by an EPS miss and weaker-than-expected adjusted EBITDA, prompting a sharp selloff. Bulls view the reaction as an overreaction to the miss and emphasize the growth outlook, while more cautious traders point to continued losses and near-term risks.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. The firm offers annealing and gate-model quantum computing technologies. It provides professional services that assist customers in identifying and implementing quantum computing applications and selling quantum computer systems to customers. The company was founded by Eric Ladizinsky in 1999 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Waves Q3 report is driving the discussion: traders are weighing revenue growth and a sizable backlog against softer bookings, continued losses, and questions about turning orders into revenue, amid a sharp selloff. Bulls point to D-Waves commercial potential and cash reserves, while bears argue its valuation remains stretched and near-term demand is unproven.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Strong Q3 results and another increase to full-year revenue guidance drove a sharp rally in SENS, with traders pointing to accelerating Eversense CGM adoption. The gains then faded, prompting debate between bullish holders who see improving commercial momentum and skeptics citing profit-taking, cash needs, and management or dilution risks.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckins Q3 results and new share-repurchase authorization are driving attention: traders highlight stronger profitability and margins, while debating whether that offsets slowing revenue growth and declining same-store sales. The reaction is split, with some viewing the shares as undervalued and others frustrated by muted price action and the lack of a relisting announcement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss — Executive ‘Disappointed,’ Reiterates Breast Cancer Focus 

Equity

A combination of the company’s breast cancer drug Etcamah did not delay worsening of the disease enough to meet the SERENA-4 late-stage trial’s main goal, AstraZeneca said. 


NVO Stock Jumps 3% As EU Approves Oral Wegovy Pill — Retail Notes LLY Is ‘Clearly Behind’ Its Danish Counterpart

Oral Wegovy is now cleared in all EU member states.


NVO Stock Gains As UK Clears First Daily GLP-1 Weight-Loss Pill, Offsetting Security Breach News

Novo Nordisk revealed that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Wegovy pill, following in the footsteps of the U.S. FDA. 


AZN Stock Rise As Wall Street Dismisses FDA Committee’s Rejection Of Breast Cancer Drug 

FDA’s Oncologic Drugs Advisory Committee (ODAC) did not reach a majority vote on the benefit-risk profile of AstraZeneca’s camizestrant in combination with other drugs. 

Novo Nordisk Launches Higher Dose Of Wegovy Injection Across US — Retail Thinks Stock Is ‘Terribly Undervalued’

The Wegovy HD injection 7.2 mg will be available through over 70,000 U.S. pharmacies including Novo’s own NovoCare Pharmacy and select telehealth providers, the company said.


Novo Nordisk Receives FDA Approval For Higher Dose Of Its Weight-Loss Drug Wegovy

The company stated that Wegovy HD received the FDA’s accelerated approval based on results from the STEP UP trial.

Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock

BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.

HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy

Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing.

Novo Nordisk To Cut Ozempic, Wegovy Prices By Up To 50%

Ozempic and Wegovy will start at a list price of $675 a month, effective Jan. 1, 2027, according to the company.

NVO Stock Continues To Decline Pre-Market After Monday’s Crash Amid CagriSema Setback – But Tuesday Brings Some Hope From China

Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.

Putnam ETF Trust - Putnam Focused Large Cap Value ETF

Bullish Sentiment

<ul class="summary-bullets"><li>AstraZeneca, however, said progression-free survival improved numerically.&nbsp;</li><li>Etcamah is a once-daily pill that breaks down the estrogen receptor many breast cancers use to grow and is already approved for a narrower group of breast cancer patients.&nbsp;</li><li>The setback lands on a pipeline already under scrutiny.</li></ul><p>Shares of AstraZeneca traded 3% lower in after-hours trading on Friday after the drugmaker said a large late-stage breast cancer study of Etcamah missed its main goal, denting hopes of a broader first-line use for one of its most closely watched oncology assets.</p><h2 class="st-heading-2">What The Trial Showed</h2><p>The trial SERENA-4 tested Etcamah plus palbociclib against a standard hormone-blocking pill plus palbociclib in 1,371 people starting treatment for advanced hormone-sensitive breast cancer that is not HER2-driven. The Etcamah combination did not delay disease progression enough to meet the trial’s main goal, though AstraZeneca said there was a numerical improvement. Side effects were in line with what is already known for both drugs. The company said it will present full results later.</p><p>Etcamah is a once-daily pill that breaks down the estrogen receptor many breast cancers use to grow. It is already approved in the United States, Europe, Japan and other markets for a narrower group: patients whose tumors pick up a common resistance mutation called ESR1 while they are on first-line hormone therapy. That use is based on an earlier SERENA-6 trial.</p><p>Friday’s miss undercuts the case for giving the drug to all newly diagnosed advanced patients from the start, before that mutation appears.</p><h2 class="st-heading-2">Another Hit After A Rough Year</h2><p>The setback lands on a pipeline already under scrutiny. In July, AstraZeneca’s heart drug Wainua failed a major heart-disease trial, triggering a steep one-day drop. Rare-disease medicine Ultomiris also missed a rare-disease study. In August, AstraZeneca halted a late-stage lung cancer trial of volrustomig after an independent committee said it was unlikely to beat standard immunotherapy.</p><p>Those blows have helped drag the stock down about 20% over six months even as core cancer sales remain a pillar of the business.</p><p>Oncology accounts for a large share of AstraZeneca’s growth. Without a broad first-line label in advanced disease, Etcamah’s near-term commercial reach is smaller. Oncology research chief Susan Galbraith called SERENA-4 disappointing but said the company remains confident in the drug’s longer-term potential in early breast cancer.</p><p>Two separate large trials, CAMBRIA-1 and CAMBRIA-2, are testing Etcamah after surgery in about 10,000 patients to see if it can cut the risk of recurrence.</p><h2 class="st-heading-2">How Did AZN Retail Traders React?</h2><p>On Stocktwits, retail sentiment around AZN stock stayed in ‘bearish’ territory over the past 24 hours, while message volume was ‘high.’</p><p><a href="https://stocktwits.com/symbol/AZN">AZN stock</a> has fallen 9% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/exel-stock-slides-after-fda-adds-three-months-to-cancer-drug-review-william-blair-sees-more-swings-in-near-term/cZtXM0eRBbg">EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

The international biopharmaceutical company Astrazeneca office building in Shanghai, China on June 27, 2025. (Photo credit should read CFOTO/Future Publishing via Getty Images)

A combination of the company’s breast cancer drug Etcamah did not delay worsening of the disease enough to meet the SERENA-4 late-stage trial’s main goal, AstraZeneca said. 

AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss — Executive ‘Disappointed,’ Reiterates Breast Cancer Focus

American Century ETF Trust - Avantis International Equity ETF

AstraZeneca PLC

Yes, by year-end

Yes, but not this year

No, he stays as CEO

He steps down on his own

Do you think Jensen Huang will be removed as Nvidia’s ($NVDA) CEO?

Stocktwits

Do you think Jensen Huang will be removed as Nvidia’s (

Feed

News

Sentiment

Fundamentals

Info

PVAL Putnam ETF Trust - Putnam Focused Large Cap Value ETF

Fundamentals

Latest PVAL News